A neuroprotective drug screening assay, which may to be the first to accurately reproduce human neurodegeneration in the lab. Its principal use is the discovery of substances that prevent brain cell death, i.e. neuroprotective drugs. Such drugs could be the first real treatments for disorders like Alzheimer's and Parksinson's. We're also in the final stages of validating a screening assay for drug-resistant epilepsy. Approximately 40% of epilepsy patients suffer from poorly controlled seizures; ~1% of the world population has epilepsy.
There are countless examples of neurological drugs (including all neuroprotective treatments) that showed promise in laboratory tests only to fail subsequent clinical trials. Clearly, these technologies are unable to predict whether or not drugs will work in people. Yet, they continue to be used.
Our approach is entirely different from the status quo. This is our advantage.